What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This slowdown was primarily due to disappointing third-quarter earnings, reduced guidance and pipeline setbacks. These challenges highlighted the inherent volatility in biotech, amplified by broader macroeconomic uncertainties. Despite these setbacks, the demand for cutting-edge medical innovations ensures the sector remains a focal point for investors.Looking ahead, innovation will continue to ...